These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. Anker SD; Schroeder S; Atar D; Bax JJ; Ceconi C; Cowie MR; Crisp A; Dominjon F; Ford I; Ghofrani HA; Gropper S; Hindricks G; Hlatky MA; Holcomb R; Honarpour N; Jukema JW; Kim AM; Kunz M; Lefkowitz M; Le Floch C; Landmesser U; McDonagh TA; McMurray JJ; Merkely B; Packer M; Prasad K; Revkin J; Rosano GM; Somaratne R; Stough WG; Voors AA; Ruschitzka F Eur J Heart Fail; 2016 May; 18(5):482-9. PubMed ID: 27071916 [TBL] [Abstract][Full Text] [Related]
3. Selection of endpoints for heart failure clinical trials. Zanolla L; Zardini P Eur J Heart Fail; 2003 Dec; 5(6):717-23. PubMed ID: 14675849 [TBL] [Abstract][Full Text] [Related]
4. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Hori M; Sasayama S; Kitabatake A; Toyo-oka T; Handa S; Yokoyama M; Matsuzaki M; Takeshita A; Origasa H; Matsui K; Hosoda S; Am Heart J; 2004 Feb; 147(2):324-30. PubMed ID: 14760332 [TBL] [Abstract][Full Text] [Related]
5. Does cardiac resynchronisation therapy improve survival and quality of life in patients with end-stage heart failure? Turley AJ; Raja SG; Salhiyyah K; Nagarajan K Interact Cardiovasc Thorac Surg; 2008 Dec; 7(6):1141-6. PubMed ID: 18541605 [TBL] [Abstract][Full Text] [Related]
7. Clinical assessment of Shenfu injection loading in the treatment of patients with exacerbation of chronic heart failure due to coronary heart disease: study protocol for a randomized controlled trial. Liu C; Hou Y; Wang X; Zhao Z; Liu Z; Zhai J; Mao J; Shang H Trials; 2015 May; 16():222. PubMed ID: 25994188 [TBL] [Abstract][Full Text] [Related]
8. Surrogate end points in heart failure. Anand IS; Florea VG; Fisher L J Am Coll Cardiol; 2002 May; 39(9):1414-21. PubMed ID: 11985901 [TBL] [Abstract][Full Text] [Related]
9. Targeting heart failure with preserved ejection fraction: current status and future prospects. Kanwar M; Walter C; Clarke M; Patarroyo-Aponte M Vasc Health Risk Manag; 2016; 12():129-41. PubMed ID: 27143907 [TBL] [Abstract][Full Text] [Related]
10. [Prognosis of mild chronic heart failure: effects of the ACE inhibitor captopril]. Kleber FX; Doering W Herz; 1991 Sep; 16 Spec No 1():283-93. PubMed ID: 1820294 [TBL] [Abstract][Full Text] [Related]
12. Beta-blockers in heart failure. Do they improve the quality as well as the quantity of life? Fowler MB Eur Heart J; 1998 Dec; 19 Suppl P():P17-25. PubMed ID: 9886708 [TBL] [Abstract][Full Text] [Related]
13. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. Bartunek J; Behfar A; Dolatabadi D; Vanderheyden M; Ostojic M; Dens J; El Nakadi B; Banovic M; Beleslin B; Vrolix M; Legrand V; Vrints C; Vanoverschelde JL; Crespo-Diaz R; Homsy C; Tendera M; Waldman S; Wijns W; Terzic A J Am Coll Cardiol; 2013 Jun; 61(23):2329-38. PubMed ID: 23583246 [TBL] [Abstract][Full Text] [Related]
14. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. Fiuzat M; Wojdyla D; Pina I; Adams K; Whellan D; O'Connor CM JACC Heart Fail; 2016 Feb; 4(2):109-115. PubMed ID: 26519996 [TBL] [Abstract][Full Text] [Related]
15. Is there an expanded role for digoxin in patients with heart failure and sinus rhythm? A protagonist viewpoint. Williamson KM; Patterson JH Ann Pharmacother; 1997; 31(7-8):888-92. PubMed ID: 9220052 [TBL] [Abstract][Full Text] [Related]
17. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). St John Sutton M; Cerkvenik J; Borlaug BA; Daubert C; Gold MR; Ghio S; Chirinos JA; Linde C; Ky B J Am Heart Assoc; 2015 Sep; 4(9):e002054. PubMed ID: 26363005 [TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: rationale and design of a randomized controlled trial. Koifman E; Grossman E; Elis A; Dicker D; Koifman B; Mosseri M; Kuperstein R; Goldenberg I; Kamerman T; Levine-Tiefenbrun N; Klempfner R Am Heart J; 2014 Dec; 168(6):830-7.e1. PubMed ID: 25458645 [TBL] [Abstract][Full Text] [Related]
19. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Cohn JN; Tognoni G; N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B; J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]